$56.14+0.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Just reported
From Cytokinetics, Incorporated's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$47.6M
+66% q/q
Guided
—
No guide given
Actual
-$1.37
Guided
—
No guide given
Actual
-$167.1M
Guided
—
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $47.6M | $1.9M | +2,356.46% |
| Profit | -$190.1M | -$306.2M | +37.92% |
| Profit per share | -$1.37 | -$2.55 | +46.27% |
| Free Cash Flow | -$124.7M | -$116.9M | -6.73% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Cytokinetics, Incorporated reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Our third quarter results demonstrate continued strong execution as Cytokinetics enters its next phase of growth as a global specialty cardiology biopharmaceutical company,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from Cytokinetics, Incorporated’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.